Technology
Health
Biotechnology

Aimmune Therapeutics

$22.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.27 (1.22%) Today
+$0.27 (1.22%) Today

Why Robinhood?

You can buy or sell AIMT and other stocks, options, ETFs, and crypto commission-free!

About

Aimmune Therapeutics, Inc. Common Stock, also called Aimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Read More Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Employees
215
Headquarters
Brisbane, California
Founded
2011
Market Cap
1.38B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
577.24K
High Today
$22.75
Low Today
$22.00
Open Price
$22.45
Volume
146.19K
52 Week High
$36.12
52 Week Low
$20.94

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Research And Development
Food

News

Simply Wall StMar 25

The Aimmune Therapeutics (NASDAQ:AIMT) Share Price Has Gained 63% And Shareholders Are Hoping For More

By buying an index fund, investors can approximate the average market return. But if you pick the right individual stocks, you could make more than that. For example, the Aimmune Therapeutics, Inc. (NASDAQ:AIMT) share price is up 63% in the last three years, clearly besting than the market return of around 38% (not including dividends). View our latest analysis for Aimmune Therapeutics Aimmune Therapeutics didn’t have any revenue in the last year, so it’s fair to say it doesn’t yet have a proven product (...

140
Associated PressMar 18

U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy

BRISBANE, Calif.--(BUSINESS WIRE)--Mar 18, 2019--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.S. Food and Drug Administration (FDA). “Today is a significant milestone for Aimmune. The FDA’s acceptance of our BLA is a crucial step forward in delivering AR101 to children, teens and families living with the serious, da...

333
MarketBeatMar 7

Stock Price, News, & Analysis for Aimmune Therapeutics

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in...

55

Earnings

-$0.95
-$0.84
-$0.74
-$0.63
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.